(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
05 October 2023 (05.10.2023)

WIPO | PCT

(10) International Publication Number
WO 2023/192901 A1

(51) International Patent Classification:
C07D 403/12 (2006.01) *A61K 31/4709* (2006.01)
C07D 403/14 (2006.01) *A61P 35/00* (2006.01)

(21) International Application Number:
PCT/US2023/065093

(22) International Filing Date:
29 March 2023 (29.03.2023)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/325,611 30 March 2022 (30.03.2022) US
63/476,920 22 December 2022 (22.12.2022) US

(71) Applicant: **ESCIENT PHARMACEUTICALS, INC.** [US/US]; 10578 Science Center Drive, Suite 250, San Diego, California 92121 (US).

(72) Inventors: **LANIER, Marion**; c/o Escient Pharmaceuticals, Inc., 10578 Science Center Drive, Suite 250, San Diego, California 92121 (US). **BOEHM, Marcus**; c/o Escient Pharmaceuticals, Inc., 10578 Science Center Drive, Suite 250, San Diego, California 92121 (US). **HUANG, Liming**; c/o Escient Pharmaceuticals, Inc., 10578 Science Center Drive, Suite 250, San Diego, California 92121 (US). **MARTINBOROUGH, Esther**; c/o Escient Pharmaceuticals, Inc., 10578 Science Center Drive, Suite 250, San Diego, California 92121 (US). **SAINZ, Marcos**; c/o Escient Pharmaceuticals, Inc., 10578 Science Center Drive, Suite 250, San Diego, California 92121 (US). **SELFRIDGE, Brandon**; c/o Escient Pharmaceuticals, Inc., 10578 Science Center Drive, Suite 250, San Diego, California 92121 (US). **YEAGER, Adam**; c/o Escient Pharmaceuticals, Inc., 10578 Science Center Drive, Suite 250, San Diego, California 92121 (US).

(74) Agent: **HERMANNS, Karl, R.** et al.; Seed Intellectual Property Law Group LLP, Suite 5400, 701 Fifth Avenue, Seattle, Washington 98104-7064 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report (Art. 21(3))*

(54) **Title:** QUINOLINE DERIVATIVES AS MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR X2 AND RELATED PRODUCTS



(I)

(57) **Abstract:** Methods are provided for modulating MRGPRX2 generally, or for treating a MRGPRX2 or a MRGPRX2 ortholog dependent condition, more specifically, by contacting the MRGPRX2 or the MRGPRX2 ortholog by administering to a subject in need thereof, respectively, an effective amount of a compound having structure (I): or a pharmaceutically acceptable salt, isomer, hydrate, solvate or isotope thereof, wherein W, Z, R^1, R^2, R^3, R^4, R^5, R^6 and R^x are as defined herein. Pharmaceutical compositions containing such compounds, as well as the compounds themselves, are also provided.

WO 2023/192901 A1